C5 Capital Partners with Ukraine’s Brave1 Accelerator to Advance Ukraine’s Defense Innovation
C5 Capital, a specialist venture capital firm based in Washington DC and London announces a strategic partnership with Brave1, Ukraine’s premier defense technology accelerator. This collaboration will support Ukraine’s innovative tech startups, accelerating the development and application of critical technologies for the defense of Ukraine against Russian aggression.
Brave1 leads Ukraine’s defense innovation ecosystem. Since its launch, the accelerator has evaluated more than 2,600 cutting-edge defense-focused innovations. This remarkable achievement has established Ukraine as emerging global leader in defense technology and innovation.
C5 Capital’s partnership will provide investment capital and strategic expertise needed to help Ukrainian founders grow and scale their defense startups, whose innovations are already being tested and deployed in battlefield conditions.
“C5 Capital’s strategic partnership with Brave1 is focused on empowering Ukraine’s courageous founders, who are building innovative companies in defense of Ukraine and all of us. Today there is nothing more important than fighting with allies,” said Andre Pienaar, the Founder of C5 Capital.
"Ukraine is emerging as a global leader in defense innovation and a powerhouse of research and development. Its defense tech startups showcase a relentless drive born from defending their homeland. We intend to bring our expertise developing and investing in innovative technologies for national defense to support victory for Ukraine,” said Rear Admiral Michael Hewitt, Co-Founder and CEO of IP3.
Ukraine: The New Hub of Defense Innovation
The conflict in Ukraine has sparked a wave of technological breakthroughs, especially in artificial intelligence (AI) and autonomous systems. Often referred to as the "algorithm war," AI-driven tools have played a pivotal role in processing vast amounts of battlefield data, enabling Ukraine to respond faster and more effectively.
Brave1 plays a crucial role in fast-tracking the development and deployment of such technologies. By connecting startups with essential resources, the accelerator transforms concepts into operational systems at an accelerated pace.
The Need for Private Investment
Brave1 issued $7.5 million in grants for startups and aims to scale funding in 2024. Over the first two years of the war, Ukrainian startups have attracted more than $20M of global investment.
“Private investment is essential for sustaining innovation in defense technology,” said Natalia Kushnerska, Brave1 Project Lead. “Our partnership with C5 is a crucial step toward building a resilient and innovative ecosystem. The technologies developed in Ukraine today will define the future of global defense.”
For more information on this strategic alliance, please visit the full article and interview published by National Security News: Ukraine Boosts Military Innovation to Confront Russian Hostilities Independently.
About C5 Capital:
C5 Capital (C5) is a specialist venture capital firm that invests in cybersecurity, space and energy security. C5's investment strategy is focused on building long-term relationships with resilient founders that share in our mission to enhance national security and build a secure digital future. C5 Capital is based in Washington, DC and London. For more information, visit: www.C5Capital.com.
About Brave1:
Brave1 is a cluster for the defense tech development in Ukraine, established by the Ministry of Digital Transformation, the Ministry of Defense, the General Staff of the Armed Forces of Ukraine, the National Security and Defense Council, the Ministry for Strategic Industries, and the Ministry of Economy. For more information, visit: https://brave1.gov.ua/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004928916/en/
Contacts
Media Contact: Reine Opperman, reine.opperman@c5capital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom